News Release

Researcher develops app to reach Black community with COVID-19 information

University of Cincinnati physician gets a boost from the Association of Black Cardiologists for study

Grant and Award Announcement

University of Cincinnati

Donald Lynch, MD, University of Cincinnati

image: Donald Lynch, MD, is shown at the University of Cincinnati College of Medicine. view more 

Credit: Photo by Colleen Kelley/UC Creative + Brand.

A University of Cincinnati cardiologist is partnering with researchers in St. Louis and rural Georgia to develop a smartphone app that will deliver COVID-19 information and education that is targeted toward Black communities.

"What we know across the country is that COVID has disproportionately affected the African American community and it is unmasking underlying disease," says Donald Lynch, MD, assistant professor of cardiovascular health and disease at UC and a UC Health cardiologist.

"I want the community to be empowered," says Lynch. "I want us to bring this mobile health-based technology into the hands of the community so it has ready access to information about COVID but also about cardiovascular disease and other areas of disease impacting African Americans disproportionately."

Lynch's work is being supported by the Association of Black Cardiologists, which awarded him $25,000 to complete a pilot study using the smartphone app.

In Ohio as of Oct. 28, 2020, there were 205,347 cases of COVID-19 which include 18,606 hospitalizations and 5,256 deaths, as reported by the Ohio Department of Health. Black residents in Ohio accounted for 14% of the population but 16.7% of COVID-19 cases and 17.1% of COVID-19 deaths. Black residents account for 25.7% of the COVID-19 hospitalizations.

Lynch is working with public health researchers, Tilicia Mayo-Gamble, PhD, at Georgia Southern University, and Kelly Harris, PhD, at Washington University in St. Louis, to conduct a yearlong study in which the smartphone app is designed based on conversations with focus groups in Cincinnati, St. Louis and Statesboro, Georgia.

"We will have a stakeholder group in each of those communities," says Lynch. "We will ask the stakeholders how people perceive they are receiving their health care information and information on COVID-19. We will ask questions about the use of smartphones."

"This is an implementation science-based project," says Lynch. "We are going to ask questions as to how satisfied they are with current available health information and what information you feel is missing. What more information is needed and where are the gaps?"

"Based on the feedback we will build our app," says Lynch. "The stakeholder conversations will conclude at the end of three months, and we hope to get a pilot version of our app available for community members to test. We know many people have access to smartphones and we think this will work well for our study."

Lynch is seeing heart patients who have recovered from COVID-19 now coming in for treatment with conditions that may be related to the pandemic.

"We are learning more and more about COVID every day, and we know COVID can affect the heart itself," says Lynch. "Now we are seeing patients that are COVID-positive. They have survived and are a month or more out and they have manifestations of heart palpitations, problems regulating blood pressure and other concerns. It's not clear if this is a result of COVID or if those symptoms were present before COVID and now we are just paying more attention to signals from our body."

Lynch participated in the 2019 PRIDE-Functional and Translational Genomics of Blood Disorder program (PRIDE-FTG) at Augusta University in Augusta, Georgia. PRIDE (Programs to Increase Diversity among Individuals Engaged in Health-Related Research) is a research career-advancing training opportunity funded by the National Heart, Lung, and Blood Institute (NHLBI) of the NIH. There Lynch met co-investigators Mayo-Gamble and Harris. The goal of PRIDE is to train junior-level faculty to do research related to blood disorders such as hemoglobinopathies and white blood cell and platelet diseases.

###


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.